
|Articles|December 1, 2004
New Products & Services
Raritan, NJ-The FDA has approved a once-a-day liquid formulation of the fluoroquinone antibiotic levofloxacin (Levaquin), from Ortho-McNeil Pharmaceutical, Inc. Levofloxacin is indicated for the treatment of a number of infections, including complicated and uncomplicated urinary tract infections, chronic bacterial prostatitis, and acute pyelonephritis.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












